Physician profile
Dania S Assad
NPI 1033556360
$3,717.34
in general payments reported to CMS, 2019-2025
48 companies · $938 in 2025
The $938 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2022: $697 · 2023: $723 · 2024: $895 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $552.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $227.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amryt Pharma Holdings LTD | $187.64 | 2022-2023 | Mycapssa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.41 | 2022-2025 | Jardiance |
| Medtronic Minimed, INC. | $187.06 | 2019 | |
| Abbvie INC. | $183.76 | 2022-2025 | Synthroid, Ubrelvy |
| Medtronic, INC. | $158.21 | 2022-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $153.77 | 2023-2024 | |
| Amgen INC. | $135.67 | 2022-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $123.02 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $111.20 | 2022-2025 | |
| Halozyme INC | $94.95 | 2023 | |
| Alvogen INC | $89.59 | 2023-2025 | Teriparatide |
| Pfizer INC. | $72.47 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $69.98 | 2023-2024 | Strensiq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $69.03 | 2022-2024 | Xyosted |
| Amneal Pharmaceuticals LLC | $64.53 | 2024-2025 | Unithroid |
| Lifescan, INC. | $64.02 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $61.44 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $58.75 | 2022-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $56.33 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $55.75 | 2022-2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $55.37 | 2022-2024 | Nexletol |
| Mannkind Corporation | $53.85 | 2023-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $48.28 | 2025 | Yorvipath |
| Dexcom, INC. | $46.62 | 2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $45.79 | 2024-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $44.16 | 2022 | |
| Beta Bionics, INC. | $42.54 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $38.30 | 2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $33.46 | 2019-2022 | |
| Horizon Therapeutics Plc | $30.97 | 2022-2023 | Tepezza |
| Amarin Pharma, INC. | $30.10 | 2022 | |
| Ascensia Diabetes Care US INC. | $25.27 | 2025 | |
| Sequel Med Tech, LLC | $23.21 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $22.91 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $21.66 | 2019 | |
| Verity Pharmaceuticals INC. | $21.55 | 2025 | Tlando |
| Eusa Pharma (US) LLC | $21.06 | 2022 | |
| Ibsa Pharma INC. | $21.00 | 2025 | Licart, Flector, Tirosint |
| Rhythm Pharmaceuticals, INC. | $20.25 | 2025 | Imcivree |
| Tolmar, INC. | $18.64 | 2025 | Jatenzo |
| Evoke Pharma, INC. | $16.77 | 2022 | |
| Kyowa Kirin, INC. | $16.15 | 2025 | |
| Cequr Corporation | $16.11 | 2024 | Cequr Simplicity |
| Valeritas, INC. | $14.77 | 2019 | |
| Currax Pharmaceuticals LLC | $12.73 | 2023 | Contrave |
| Theracosbio, LLC | $10.84 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dania Assad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.